The recent FDA approval of Madrigal’s resmetirom as the first ever, disease-specific treatment for NASH marks a historic milestone in a field beset by many disappointments and high profile failures. It also signals the beginning of the emergence of a commercial market for NASH pharmacotherapies.
While resmetirom is the first, it may not enjoy its status for too long, as several, late-stage NASH assets race to cross the regulatory finish line, among them potent, incretin-targeting anti-obesity therapies which have also demonstrated remarkable results in NASH. However, all of them face formidable challenges in converting significant unmet need – an estimated >100 million NASH cases globally by 2030 – into a commercial market.
In this white paper, learn more about this highly dynamic field, the barriers and critical success factors for developing and commercialising NASH therapies, and take a deep dive into the transformation of how NASH is diagnosed, which holds the key to unlocking the NASH opportunity.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Discover new approaches to cardiovascular clinical trials to bring game-changing therapies to patients faster.
.svg){kind=icon}
